Y0002224

Sorafenib tosilate

CRS, European Pharmacopoeia (EP) Reference Standard

• Sinónimos: Sorafenib tosylate, 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, 4-methylbenzenesulfonate, BAY 43-9006 tosylate salt, BAY43-9006 tosylate salt, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, 4-methylbenzenesulfonate
• Fórmula empírica (notación de Hill): C₂₁H₁₆ClF₃N₄O₃·C₇H₈SO₃
• Número de CAS: 475207-59-1
• Peso molecular: 637.03
• Número MDL: MFCD08235032
• Código UNSPSC: 41116107
• NACRES: NA.24

Propiedades

• familia API: sorafenib
• fabricante / nombre comercial: EDQM
• temp. de almacenamiento: 2-8°C
• cadena SMILES: FC(F)(F)c2c(ccc(c2)NC(=O)Nc3ccc(cc3)Oc4cc([n+H]cc4)C(=O)NC)Cl.[S](=O)(=O)([O-])c1ccc(cc1)C
• InChI: 1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
• Clave InChI: IVDHYUQIDRJSTI-UHFFFAOYSA-N

Descripción

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Sorafenib tosilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Orally active kinase inhibitor that exerts anticancer efficacy via targeting Raf-1 (c-Raf), b-Raf, VEGFR-2 (Flk-1, KDR), VEGFR-3, PDGFR-β, Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Tosylate salt of the orally active kinase inhibitor Sorafenib (BAY 43-9006) that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-β), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Información de seguridad

• Pictogramas: GHS08,GHS09
• Palabra de señalización: Danger
• Frases de peligro: H360FD,H362,H372,H410
• Consejos de prudencia: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Clasificaciones de peligro: Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
• Código de clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable